Innovative research focuses on improving prostate cancer outcomes
Research investigating the ability to detect low levels of circulating tumor cells and to correlate their quantity with clinicopathologic parameters in men with advanced prostate cancer who have undergone surgery or radiotherapy is still at an early stage, but the initial results suggest this method has promising prognostic value.
Key Points
In terms of the latter, the potential for measuring circulating tumor cells as a prognostic marker, use of new compounds for halting cancer progression and treatment-related risks, and vaccine therapy are three areas that may generate the greatest interest, according to J. Brantley Thrasher, MD.
"There is a lot of innovative research under way focusing on improving outcomes for men with advanced prostate cancer," said Dr. Thrasher, professor and chair of urology, University of Kansas Medical Center, Kansas City. "That makes me excited about the AUA meeting and anxious to hear more about these areas."
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
